Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1960 1
1964 1
1967 1
1968 1
1970 1
1971 1
1972 2
1973 1
1974 2
1975 1
1976 1
1977 1
1978 1
1979 5
1980 2
1981 1
1984 1
1985 4
1986 2
1987 1
1988 1
1989 8
1990 2
1991 4
1992 4
1993 6
1994 9
1995 14
1996 11
1997 16
1998 16
1999 15
2000 12
2001 13
2002 7
2003 6
2004 13
2005 16
2006 33
2007 21
2008 23
2009 28
2010 28
2011 22
2012 45
2013 52
2014 34
2015 35
2016 50
2017 50
2018 56
2019 55
2020 59
2021 85
2022 66
2023 25
Text availability
Article attribute
Article type
Publication date

Search Results

878 results
Results by year
Filters applied: . Clear all
Page 1
Defective Epstein-Barr virus in chronic active infection and haematological malignancy.
Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, Inoue M, Kawa K, Seto M, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Narita Y, Yoshida M, Goshima F, Kawada JI, Nishida T, Kiyoi H, Kato S, Nakamura S, Morishima S, Yoshikawa T, Fujiwara S, Shimizu N, Isobe Y, Noguchi M, Kikuta A, Iwatsuki K, Takahashi Y, Kojima S, Ogawa S, Kimura H. Okuno Y, et al. Among authors: narita y. Nat Microbiol. 2019 Mar;4(3):404-413. doi: 10.1038/s41564-018-0334-0. Epub 2019 Jan 21. Nat Microbiol. 2019. PMID: 30664667
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, Tai DWM, Choo SP, Zhai W, Lim JQ, Das Thakur M, Molinero L, Cha E, Fasso M, Niger M, Pietrantonio F, Lee J, Jeyasekharan AD, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng CCY, Rha SY, Narita Y, Muro K, Guo YA, Skanderup AJ, So JBY, Yong WP, Chen Q, Göke J, Tan P. Sundar R, et al. Among authors: narita y. Gut. 2022 Jul;71(7):1277-1288. doi: 10.1136/gutjnl-2021-324420. Epub 2021 Aug 25. Gut. 2022. PMID: 34433583 Free PMC article.
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T, Machida R, Kuchiba A, Maehara T, Nagane M, Nishikawa R, Suzuki H, Shibuya M, Komori T, Narita Y, Ichimura K. Fujimoto K, et al. Among authors: narita y. Acta Neuropathol. 2021 Aug;142(2):323-338. doi: 10.1007/s00401-021-02337-9. Epub 2021 Jun 20. Acta Neuropathol. 2021. PMID: 34148105
Bevacizumab for glioblastoma.
Narita Y. Narita Y. Ther Clin Risk Manag. 2015 Dec 1;11:1759-65. doi: 10.2147/TCRM.S58289. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26664126 Free PMC article. Review.
IDH1/2 mutation detection in gliomas.
Arita H, Narita Y, Yoshida A, Hashimoto N, Yoshimine T, Ichimura K. Arita H, et al. Among authors: narita y. Brain Tumor Pathol. 2015 Apr;32(2):79-89. doi: 10.1007/s10014-014-0197-x. Epub 2014 Jul 10. Brain Tumor Pathol. 2015. PMID: 25008158 Review.
Reverse Engineering Glioma Radiomics to Conventional Neuroimaging.
Kinoshita M, Kanemura Y, Narita Y, Kishima H. Kinoshita M, et al. Among authors: narita y. Neurol Med Chir (Tokyo). 2021 Sep 15;61(9):505-514. doi: 10.2176/nmc.ra.2021-0133. Epub 2021 Aug 6. Neurol Med Chir (Tokyo). 2021. PMID: 34373429 Free PMC article. Review.
878 results